Navigation Links
Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
Date:5/7/2009

Safety and Efficacy Data from Phase 3 Study will be Highlighted

SAN DIEGO, May 7 /PRNewswire-USNewswire/ -- Chronic pain is a significant medical challenge in the United States, and chronic low back pain is the most common cause of disability in developed countries. An estimated 100 million Americans suffer from chronic pain each year. If left undertreated, chronic pain can impair an individual's ability to carry out daily activities and diminish quality of life.

Three clinical presentations about the use of tapentadol extended release tablets to treat patients with chronic low back pain, including pivotal Phase 3 safety, efficacy and gastrointestinal tolerability data, will be discussed during the poster sessions of the 28th Annual Scientific Meeting of the American Pain Society (APS) in San Diego, California on Thursday, May 7, and Friday, May 8, 2009. These data presentations are supported by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD).

Tapentadol binds to mu-opioid receptors and inhibits norepinephrine re-uptake. Although the exact mechanism of action is not known, these two mechanisms, which affect established pain pathways, are thought to be responsible for pain relief with tapentadol. The U.S. Drug Enforcement Agency has proposed placing the tapentadol molecule into Schedule II of the Controlled Substances Act.

J&JPRD continues to study tapentadol extended release formulation for chronic pain, and a New Drug Application (NDA) is planned for submission to the United States Food and Drug Administration (FDA) this year. The NDA filing is part of the ongoing commitment of J&JPRD and PriCara(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., to bring new and innovative products to patients and physicians for the treatment and management of pain.

The following posters on tapentadol extended release data will
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
2. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
3. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
4. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
5. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
6. Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
7. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
8. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
9. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
10. Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO08
11. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Alemania, December 17, 2014 Los ... con un alto nivel de gasto en investigación y ... 2013/14 (finalizado el 30 de septiembre de 2014) ZEISS ... 4.287 millones de euros (año anterior: 4.190 millones de ... desfavorables. Las ganancias (EBIT) crecieron un 14 por ciento, ...
(Date:12/17/2014)... NEW YORK , Dec. 17, 2014 /PRNewswire-USNewswire/ ... resonance imaging (MRI), the MRI market is seeing ... cardiovascular and breast MRI scans account for the ... providing a higher resolution of images, which are creating ... resonance imaging (MRI) market is growing at a ...
(Date:12/17/2014)... N.J. , Dec. 17, 2014  IGI Laboratories, ... today the closing of its offering of $125 million ... 2019 (the "Notes").  The Notes were offered and sold ... under the Securities Act of 1933, as amended (the ... a fixed rate of 3.75% per year, payable semiannually ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... PSTX) today announced that The Mount Sinai Hospital in New York City has implemented its Safety-Sponge System. , ... , , ... ... ...
... N.J. , March 15 Regado Biosciences, Inc., ... with active control agents, announced that Chris Rusconi , ... Zelenkofske , DO, FACC, Senior Vice President , Chief Medical ... on Monday, March 15, 2010 in Atlanta, ...
Cached Medicine Technology:Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York 2Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York 3Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 2Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 3Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 4
(Date:12/19/2014)... Wisconsin (PRWEB) December 19, 2014 After ... music performer is again returning to the stage to ... her husband for concert performances, and the successful tour ... was originally announced. , Visit Ticketability.com ... the newly-announced Detroit shows at fair prices. , Music ...
(Date:12/19/2014)... good shape seems to reduce your risk of high blood ... than 57,000 Americans, including more than 35,000 with high blood ... Those in the poorest shape had a more than 70 ... of the study, compared to a 50 percent chance for ... than 8,000 people diagnosed with high blood pressure during the ...
(Date:12/19/2014)... Dotinga HealthDay Reporter ... including ibuprofen, might slightly reduce your risk of developing ... of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to ... 15 percent, the researchers concluded after reviewing nine prior ... sun exposure. These painkillers "have potential ...
(Date:12/17/2014)... FL (PRWEB) December 17, 2014 While countless ... people do not realize the potential dangers of their purchase. ... valid prescription from a qualified doctor, but patients who buy ... the point that there is actually no real hCG present. ... States, where there are no safety standards and may contain ...
(Date:12/17/2014)... 17, 2014 HeartMath® Inc., recognized ... stress, heart rate variability (HRV), heart coherence and ... extensive HRV databases and algorithms to chipset manufacturers ... enable HeartMath’s partners to offer its HRV solutions, ... as well as its normative HRV databases and ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3
... June 24 Lightspeed Design, Inc. announces the release ... state-of-the-art capture and playback of HD 3D media. DepthQ(R) ... professional clients in corporate, entertainment, medical and industrial applications ... new DepthQ(R) family of stereoscopic software -- DepthQ(R)Capture(TM) and ...
... Dr. Marc Sarti from the University of Virginia ... to target small cancerous lung lesions that were located in extremely ... for the diagnosis and treatment for these patients was the first ... the lungs, small potential cancers are extremely difficult to access for ...
... every online purchase of new Maui Jim sunglasses results in a ... , LAHAINA, Hawaii, June 24 Effective today and extending ... Jim sunglasses from http://www.mauijim.com will ... to Unite for Sight, the preeminent non-profit group dedicated to improvement ...
... to participate in the Foundation,s Orange ... , NEW YORK, June 24 The Crohn,s & Colitis Foundation, ... from the second annual Celebrating UC Success essay contest. ... program that honors people who have found personal ways to manage ...
... Surveyed Physicians Will Increase Their Use of Carbapenems In ... from AMR and Decision Resources , , MALVERN, ... Arlington Medical Resources (AMR) and Decision Resources find ... a leading drug attribute that surveyed physicians prefer for ...
... Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - ... of recovering intellectual property (IP) rights that could provide ... Company retained a USA based IP consultant to attempt ... preferred shareholder and its corporate advisors, verily believe was ...
Cached Medicine News:Health News:Lightspeed Releases the New DepthQ(R) Family of Stereoscopic HD Video Software 2Health News:Lightspeed Releases the New DepthQ(R) Family of Stereoscopic HD Video Software 3Health News:Veran Medical Enables Breakthrough 4D Navigation to Cancer Lesions at University of Virginia Hospital 2Health News:Maui Jim Teams With Unite for Sight in New 'Buy One, Give One' Program to Improve Eye Health Amongst the World's Most Needy 2Health News:Maui Jim Teams With Unite for Sight in New 'Buy One, Give One' Program to Improve Eye Health Amongst the World's Most Needy 3Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 2Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 3Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 4Health News:The Crohn's & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners 5Health News:Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting 2Health News:Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting 3Health News:Hard To Treat Diseases (HTDS.PK) To Regain Intellectual Property (IP) Ownership 2Health News:Hard To Treat Diseases (HTDS.PK) To Regain Intellectual Property (IP) Ownership 3
For the quantitative determination of direct & total bilirubin in serum. Modified Malloy-Evelyn Diazotization Method. Endpoint Reaction Product measured at 540 nm. Linearity: 20 mg/dl...
... Powerwave is the first microplate spectrophotometer designed ... 7 days per week. With rugged hardware, ... Powerwave breaks the barrier of traditional spectrophotometry ... One instrument can easily read up to ...
... Spectrophotometers are simple, reliable ... use in many types ... clinical, industrial and environmental ... vial holders, Windows based ...
Spectra 3000RS & Spectra 3000RSP are very precise instruments. They have a metal base structure, durable parts for long life use, and they are very easy to use and maintain....
Medicine Products: